Join
Live feed
·
PRReleasevia Quantisnow
Altimmune Inc. logo

Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH

ByQuantisnow·Wall Street's wire, on your screen.
ALT· Altimmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALT (Altimmune Inc.) and more on Quantisnow.